Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Etoricoxib
| Description | |
|---|---|
| 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridine | |
| 202409-33-4 | |
| C18H15CIN2O2S | |
| Algix;Etoxib;Etocox;MK 663;Tauxib;Etobrix;Arcoxia;Kingcox;MK 0663;Etropain | |
| For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. | |
Copyright © 2014. All Rights Reserved at Jai Radhe Sales.
Powered by: Adit Microsys
